The UCL spinout has secured an additional licence to a protein that aims to reduce side effects associated with its Car T immuno-oncological approach.
University College London (UCL) has granted a licence to commercialise a T-cell therapy targeting malignant blood cancers to Autolus, a UK-based immunooncology developer spun out from the institution.
UCL Business, the university’s tech transfer office, was responsible for conducting the licence agreement.
The agreement covers an asset designated Auto1 that genetically modifies T-cells in a patient’s immune system to activate a cellular process, called CD19-CAR T, which could fight blood cancers such as leukaemia and lymphoma.
Auto1, currently undergoing phase…
